AVITA Medical’s PermeaDerm Cuts Wound Care Costs by 70% with Comparable Outcomes

• 70% reduction in product cost per percent TBSA treated
• 96% lower preparation time versus allograft
• Comparable graft take and wound healing rates
• Study involved 40 patients across 11 US burn centres
• Off-the-shelf availability simplifies hospital workflows

PermeaDerm Demonstrates Major Cost Savings in Wound Care

AVITA Medical (ASX:AVH) has unveiled compelling data from its PermeaDerm-I clinical trial showing its biosynthetic wound matrix delivers a staggering 70% economic advantage over traditional cadaveric allograft for temporary wound coverage. The multicenter randomized controlled study enrolled 40 patients with acute wounds across 11 US burn centres, comparing PermeaDerm directly with allograft during the critical temporization phase before definitive skin grafting.

PermeaDerm reduced the mean product cost per percent total body surface area (TBSA) treated to $148.70, sharply lower than the $497.10 seen with allograft, translating to savings of roughly $348 per percent TBSA. This cost benefit was statistically significant (p<0.001) and reflects both the product price and logistical efficiencies.

Efficiency Gains Through Off-the-Shelf Availability

A key driver of PermeaDerm’s economic edge is its off-the-shelf availability, which slashed preparation time by 95.7% compared to allograft. Unlike allograft, PermeaDerm requires no thawing, meshing, or tissue tracking, streamlining hospital workflows and reducing operating room delays. Application times in surgery were comparable between the two treatments.

Clinical outcomes remained on par with allograft. Approximately 94% of patients treated with PermeaDerm achieved at least 95% graft take one week post-autografting, matching the allograft cohort. By eight weeks, all patients in both groups had attained 95% or greater wound healing. Importantly, no adverse events were linked to PermeaDerm during the trial.

Clinical Endorsements and Market Implications

Dr Anju Saraswat, Associate Burn Director at Atrium Health Wake Forest Baptist Burn Center and a study investigator, highlighted the transparency of PermeaDerm as a clinical advantage, allowing direct visualization of the wound bed without product removal. This feature, combined with the elimination of tissue bank logistics, offers a more efficient and cost-effective approach to wound temporization without compromising healing outcomes.

AVITA Medical’s CEO Cary Vance framed the findings as validation of PermeaDerm as a "modern alternative to allograft," combining clinical parity with significant economic value and a simplified workflow. This positions PermeaDerm as a strategic asset within AVITA’s acute wound care portfolio, which also includes RECELL and Cohealyx.

The PermeaDerm-I study’s relatively small sample size and eight-week follow-up period suggest further investigation and real-world adoption will be critical to confirming these promising results. However, the data arrives amid AVITA’s broader growth momentum, following recent revenue upgrades driven by RECELL and Cohealyx sales, and a push toward cash flow breakeven by year-end.

Upcoming Webinar to Discuss Clinical Data

AVITA will host a Key Opinion Leader webinar on August 18 featuring Dr Saraswat and Dr Christina Sharon, Burn Center Director at Baton Rouge General. The session aims to delve deeper into the PermeaDerm-I data and clinical experience, offering investors and clinicians a direct line to expert insights.

Bottom Line?

PermeaDerm’s strong cost and efficiency profile could reshape temporary wound coverage, but wider adoption and longer-term data remain key hurdles.

Questions in the middle?

• Will PermeaDerm’s cost savings translate into faster hospital adoption and reimbursement support?
• How will PermeaDerm perform in larger, more diverse patient populations and longer-term follow-up?
• Can AVITA leverage PermeaDerm’s advantages to gain market share against entrenched allograft suppliers?